Potentially Resectable EGFR Exon 20 Insertion Non-Small Cell Lung Cancer
1 clinical trials · Condition
◉ Watch Potentially Resectable EGFR Exon 20 Insertion Non-Small Cell Lung Cancer
| Record | Firm | Date |
|---|---|---|
| Neoadjuvant Sunvozertinib in Stage II-IIIB Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutation. (NCT07274761) | Shanghai Pulmonary Hospital, Shanghai, China | 2024-10-17 |
Track Potentially Resectable EGFR Exon 20 Insertion Non-Small Cell Lung Cancer automatically
Every clearance here is in the API, with alerts when new ones post.